SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) in an aggressive malignancy with suboptimal response to frontline chemotherapy and without established second line treatment. cMET activation is associated with ACC resistance to chemotherapy. Cabozantinib is a multi-kinase inhibitor that targets the VEGFR,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedrose, Sara Shokry Daniel, Altameemi, Lina, Daher, Marilyne, De Rosa, Gina Tamsen, Varghese, Jeena Mary, Jimenez, Camilo, Campbell, Matthew, Habra, Mouhammed Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209711/
http://dx.doi.org/10.1210/jendso/bvaa046.508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209711/
http://dx.doi.org/10.1210/jendso/bvaa046.508

Ejemplares similares